DSKYF Quote, Financials, Valuation and Earnings

PeptiDream has a net margin of 19.58% compared to Daiichi Sankyo's net margin of -5.57%. Daiichi Sankyo's return on equity of 12.79% beat PeptiDream's return on equity of 34.66%.

Daiichi Sankyo has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Daiichi Sankyo has higher upside potential than PeptiDream, analysts believe Daiichi Sankyo is more attractive than PeptiDream.

Daiichi Sankyo has a beta of 0.348, which suggesting that the stock is 65.169% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.826, suggesting its less volatile than the S&P 500 by 17.389%.

Daiichi Sankyo has a quarterly dividend of $0.21 per share corresponding to a yield of 1.5%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daiichi Sankyo pays 33.42% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend. Daiichi Sankyo's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Daiichi Sankyo quarterly revenues are $2.8B, which are larger than PeptiDream quarterly revenues of $36.8M. Daiichi Sankyo's net income of $547.7M is higher than PeptiDream's net income of -$2.1M. Notably, Daiichi Sankyo's price-to-earnings ratio is 34.06x while PeptiDream's PE ratio is 20.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daiichi Sankyo is 4.60x versus 7.14x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

Nxera Pharma has a net margin of 19.58% compared to Daiichi Sankyo's net margin of 12.96%. Daiichi Sankyo's return on equity of 12.79% beat Nxera Pharma's return on equity of -5.58%.

Daiichi Sankyo has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Daiichi Sankyo has higher upside potential than Nxera Pharma, analysts believe Daiichi Sankyo is more attractive than Nxera Pharma.

Daiichi Sankyo has a beta of 0.348, which suggesting that the stock is 65.169% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.337, suggesting its less volatile than the S&P 500 by 66.345%.

Daiichi Sankyo has a quarterly dividend of $0.21 per share corresponding to a yield of 1.5%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daiichi Sankyo pays 33.42% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend. Daiichi Sankyo's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Daiichi Sankyo quarterly revenues are $2.8B, which are larger than Nxera Pharma quarterly revenues of $62.4M. Daiichi Sankyo's net income of $547.7M is higher than Nxera Pharma's net income of $8.1M. Notably, Daiichi Sankyo's price-to-earnings ratio is 34.06x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daiichi Sankyo is 4.60x versus 2.79x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Takeda Pharmaceutical has a net margin of 19.58% compared to Daiichi Sankyo's net margin of 7.83%. Daiichi Sankyo's return on equity of 12.79% beat Takeda Pharmaceutical's return on equity of 4.01%.

Daiichi Sankyo has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $16.03 which suggests that it could grow by 20.8%. Given that Takeda Pharmaceutical has higher upside potential than Daiichi Sankyo, analysts believe Takeda Pharmaceutical is more attractive than Daiichi Sankyo.

Daiichi Sankyo has a beta of 0.348, which suggesting that the stock is 65.169% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.498, suggesting its less volatile than the S&P 500 by 50.209%.

Daiichi Sankyo has a quarterly dividend of $0.21 per share corresponding to a yield of 1.5%. Takeda Pharmaceutical offers a yield of 4.7% to investors and pays a quarterly dividend of $0.33 per share. Daiichi Sankyo pays 33.42% of its earnings as a dividend. Takeda Pharmaceutical pays out 199.34% of its earnings as a dividend. Daiichi Sankyo's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical's is not.

Daiichi Sankyo quarterly revenues are $2.8B, which are smaller than Takeda Pharmaceutical quarterly revenues of $7.9B. Daiichi Sankyo's net income of $547.7M is lower than Takeda Pharmaceutical's net income of $619.7M. Notably, Daiichi Sankyo's price-to-earnings ratio is 34.06x while Takeda Pharmaceutical's PE ratio is 21.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daiichi Sankyo is 4.60x versus 1.39x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.